Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates

Vaccine

Volumn 30, Issue 16, 2012, Pages 2662-2670

  Annoura, Takeshi ^a   Ploemen, Ivo H J ^b   van Schaijk, Ben C L ^b   Sajid, Mohammed ^a   Vos, Martijn W ^b   van Gemert, Geert Jan ^b   Chevalley Maurel, Severine ^a   Franke Fayard, Blandine M D ^a   Hermsen, Cornelus C ^b   Gego, Audrey ^c,d   Franetich, Jean Francois ^c,d   Mazier, Dominique ^c,d,e   Hoffman, Stephen L ^f   Janse, Chris J ^a   Sauerwein, Robert W ^b   Khan, Shahid M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f SANARIA INC   (United States)

Author keywords

FABB F; Genetically attenuated parasites; In vivo imaging; Malaria; P36; P52; Plasmodium; Rodent models

Indexed keywords

PROTEIN P 36; PROTEIN P52; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DNA MODIFICATION; GENE DELETION; GENE REPLICATION; GENETIC MANIPULATION; LIVER DEVELOPMENT; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; FEMALE; GENE DELETION; GENES, REPORTER; HEPATOCYTES; HOST SPECIFICITY; HUMANS; LIVER; LUCIFERASES; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SPOROZOITES; VACCINES, ATTENUATED;

EID: 84858298741     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.010     Document Type: Article

References (37)

1. Hoffman S.L., Goh L.M., Luke T.C., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185(April (8)):1155-1164.
2. Nussenzweig R., Vanderberg J.P., Most H., Orton C. Protective immunity produced by injection of X-irradiated sporozoites of Plasmodium Berghei. Nature 1967, 216(5111):160.
3. Hoffman S.L., Billingsley P.F., James E., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010, 6(January (1):97-106.
4. Kappe S.H., Vaughan A.M., Boddey J.A., Cowman A.F. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010, 328(May (5980)):862-866.
5. Pinzon-Charry A., Good M.F. Malaria vaccines: the case for a whole-organism approach. Expert Opin Biol Ther 2008, 8(April (4)):441-448.
6. Kester K.E., Cummings J.F., Ofori-Anyinam O., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(August (3)):337-346.
7. Mueller A.K., Camargo N., Kaiser K., et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci U S A 2005, 102(February (8)):3022-3027.
8. Mueller A.K., Labaied M., Kappe S.H.I., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433(January (7022)):164-167.
9. van Dijk M.R., Douradinha B., Franke-Fayard B., et al. Genetically attenuated P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A 2005, 102(August (34)):12194-12199.
10. Purcell L.A., Yanow S.K., Lee M., Spithill T.W., Rodriguez A. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun 2008, 76(March (3)):1193-1199.
11. Purcell L.A., Wong K.A., Yanow S.K., Lee M., Spithill T.W., Rodriguez A. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine 2008, 26(September (8)):4880-4884.
12. + T cells. J Infect Dis 2007, 196(August (4)):599-607.
13. Kumar K.A., Baxter P., Tarun A.S., Kappe S.H., Nussenzweig V. Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites. PLoS One 2009, 4(2):e4480.
14. Mueller A.K., Deckert M., Heiss K., Goetz K., Matuschewski K., Schluter D. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am J Pathol 2007, 171(July (1)):107-115.
15. Hafalla J.C., Rai U., Morrot A., Bernal-Rubio D., Zavala F., Rodriguez A. Priming of CD8+ T cell responses following immunization with heat-killed Plasmodium sporozoites. Eur J Immunol 2006, 36(May (5)):1179-1186.
16. Spitalny G.L., Nussenzweig R.S. Effect of various routes of immunization and methods of parasite attenuation on development of protection against sporozoite-induced rodent malaria. Proceedings of the helminthological society of Washington, vol. 39 (November) 1972, 506-514.
17. Scheller L.F., Stump K.C., Azad A.F. Plasmodium berghei: production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice. J Parasitol 1995, 81(February (1)):58-62.
18. Vaughan A.M., Wang R., Kappe S.H. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010, 6(January (1)):107-113.
19. Aly A.S., Mikolajczak S.A., Rivera H.S., et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 2008, 69(July (1)):152-163.
20. Silvie O., Goetz K., Matuschewski K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 2008, 4(June (6)):e1000086.
21. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007, 75(August (8)):758-768.
22. Vaughan A.M., O'Neill M.T., Tarun A.S., et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 2009, 11(March (3)):506-520.
23. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9(June (6)):451-462.
24. Aly A.S., Lindner S.E., MacKellar D.C., Peng X., Kappe S.H. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. Mol Microbiol 2011, 79(February (4)):929-939.
25. Douradinha B., van Dijk M.R., Ataide R., et al. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int J Parasitol 2007, 37(May (13)):1511-1519.
26. Tarun A.S., Vaughan A.M., Kappe S.H. Redefining the role of de novo fatty acid synthesis in Plasmodium parasites. Trends Parasitol 2009, 25(December (12)):545-550.
27. VanBuskirk K.M., O'Neill M.T., de l V., et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A 2009, 106(August (31)):13004-13009.
28. Ploemen I.H., Prudencio M., Douradinha B.G., et al. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One 2009, 4(11):e7881.
29. Gerloff D.L., Creasey A., Maslau S., Carter R. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc Natl Acad Sci U S A 2005, 102(September (38)):13598-13603.
30. van Dijk M.R., van Schaijk B.C., Khan S.M., et al. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog 2010, 6(April (4)):e1000853.
31. Ishino T., Chinzei Y., Yuda M. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol Microbiol 2005, 58(December (5)):1264-1275.
32. Sharma S., Sharma S.K., Surolia N., Surolia A. Beta-ketoacyl-ACP synthase I/II from Plasmodium falciparum (PfFabB/F)-is it B or F?. IUBMB Life 2009, 61(June (6)):658-662.
33. van Schaijk B.C., Vos M.W., Janse C.J., Sauerwein R.W., Khan S.M. Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase. PLoS One 2010, 5(11):e15121.
34. van Schaijk B.C., Janse C.J., van Gemert G.J., et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One 2008, 3(10):e3549.
35. Yu M., Kumar T.R., Nkrumah L.J., et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 2008, 4(December (6)):567-578.
36. Matuschewski K., Ross J., Brown S.M., Kaiser K., Nussenzweig V., Kappe S.H.I. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. J Biol Chem 2002, 277(November (44)):41948-41953.
37. Kappe S. Genetically engineered malaria parasite vaccine approaches: Current status. American Society of Tropical Medicine and Hygiene Meeting 2010. Report No.: Symposium 150.